thecardiologyadvisor.com1h
Abelacimab Reduces Bleeding Risk Better Than Rivaroxaban in AF With Stroke Risk
Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.
Medscape3h
DOACs Beneficial in Patients With ICH and Comorbid AF?
Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.
Early diagnosis, advancements in treating atrial fibrillation lead to better outcomes
A rapid heartbeat and shortness of breath could be signs of atrial fibrillation (AFib), an irregular heartbeat. Dr. Jim Stone, a cardiac electrophysiologist at North Medical Center in Tupelo, helps ...
The American Journal of Managed Care1d
Abelacimab Shows Potential to Shift the Standard of Care in AFib
Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.
Long Island Press1d
Heart health: Treating Afib can prevent strokes, cardiac deaths
If left untreated, Afib can lead to stroke, heart failure and premature cardiac death. But fortunately, Afib is treatable and, in some cases, preventable.
Novartis1d
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
Chronic inflammation's connection to atrial fibrillation points to IL-1β as a promising treatment target
A recent Brazilian study published in Nature Cardiovascular Research has highlighted promising pathways for preventing and ...